Literature DB >> 26093626

High Incidence of Serologic Markers of Inflammatory Bowel Disease in Asymptomatic Patients with Glycogen Storage Disease Type Ia.

Nicole T Lawrence1, Tayoot Chengsupanimit2, Laurie M Brown2, David A Weinstein3.   

Abstract

Most patients with glycogen storage disease (GSD) type Ib show features related to inflammatory bowel disease (IBD). The development of IBD seems to be associated with the defect of neutrophil function in GSD Ib. Patients with GSD Ia were not recognized to have similar gastrointestinal complaints until recently and are not associated with a neutrophil defect. Fifty consecutive GSD Ia inpatients over the age of 2 years without a diagnosis of IBD were screened using serologic and genetic markers via the Prometheus IBD sgi Diagnostic test. Eleven patients were tested positive for IBD (22%), with five fitting the pattern for Crohn's disease, five for ulcerative colitis, and one with nonspecific IBD. Only 2 out of the 11 patients had any gastrointestinal complaints. No pattern could be distinguished from individual inflammatory markers, genetics, inflammation antibodies, age, complications, or metabolic control. Of note, 9 out of 11 patients testing positive were female. Patients with GSD Ia were found to have a higher rate of serologically indicated IBD when compared with the general population. While these subjects will need to be followed to determine if these serologic markers correlate with clinical disease, this study supports that IBD may be more common in the GSD Ia population. Further studies are warranted to explain the relationship between IBD and GSD I since it may provide clues regarding the pathogenesis of IBD development in the general population.

Entities:  

Year:  2015        PMID: 26093626      PMCID: PMC4582023          DOI: 10.1007/8904_2015_452

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  27 in total

1.  Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I).

Authors:  Jan Peter Rake; Gepke Visser; Philippe Labrune; James V Leonard; Kurt Ullrich; G Peter A Smit
Journal:  Eur J Pediatr       Date:  2002-08-22       Impact factor: 3.183

2.  National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States.

Authors:  Geoffrey C Nguyen; Christopher A Chong; Rachel Y Chong
Journal:  J Crohns Colitis       Date:  2013-09-24       Impact factor: 9.071

3.  The entire predictive value of the prometheus IBD sgi diagnostic product may be due to the three least expensive and most available components.

Authors:  Brian Shirts; Alexander C von Roon; Anne E Tebo
Journal:  Am J Gastroenterol       Date:  2012-11       Impact factor: 10.864

4.  Inflammatory Bowel Disease in Glycogen Storage Disease Type Ia.

Authors:  Nicole T Lawrence; Tayoot Chengsupanimit; Laurie M Brown; Terry G J Derks; G Peter A Smit; David A Weinstein
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

5.  Effect of continuous glucose therapy begun in infancy on the long-term clinical course of patients with type I glycogen storage disease.

Authors:  J I Wolfsdorf; J F Crigler
Journal:  J Pediatr Gastroenterol Nutr       Date:  1999-08       Impact factor: 2.839

6.  Antibodies to CBir1 are associated with glycogen storage disease type Ib.

Authors:  Michael K Davis; John F Valentine; David A Weinstein; Steven Polyak
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-07       Impact factor: 2.839

7.  Hepatocellular carcinoma in type I glycogen storage disease.

Authors:  J Limmer; W E Fleig; D Leupold; R Bittner; H Ditschuneit; H G Beger
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

8.  Inflammatory bowel disease in glycogen storage disease type Ib.

Authors:  T F Roe; D W Thomas; V Gilsanz; H Isaacs; J B Atkinson
Journal:  J Pediatr       Date:  1986-07       Impact factor: 4.406

9.  Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I.

Authors:  Richard D Beegle; Laurie M Brown; David A Weinstein
Journal:  JIMD Rep       Date:  2014-10-12

10.  Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics.

Authors:  Jonas Halfvarson; Lennart Bodin; Curt Tysk; Eva Lindberg; Gunnar Järnerot
Journal:  Gastroenterology       Date:  2003-06       Impact factor: 22.682

View more
  5 in total

1.  Effect of VSL#3 Probiotic in a Patient with Glycogen Storage Disease Type Ia and Irritable Bowel Disease-like Disease.

Authors:  Miguel Carnero-Gregorio; Alberto Molares-Vila; Alberte Corbalán-Rivas; Carlos Villaverde-Taboada; Carmen Rodríguez-Cerdeira
Journal:  Probiotics Antimicrob Proteins       Date:  2019-03       Impact factor: 4.609

2.  Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy.

Authors:  Elizabeth D Brooks; Dustin J Landau; Jeffrey I Everitt; Talmage T Brown; Kylie M Grady; Lauren Waskowicz; Cameron R Bass; John D'Angelo; Yohannes G Asfaw; Kyha Williams; Priya S Kishnani; Dwight D Koeberl
Journal:  J Inherit Metab Dis       Date:  2018-07-24       Impact factor: 4.982

3.  Hepatic glycogen storage diseases are associated to microbial dysbiosis.

Authors:  Karina Colonetti; Bruna Bento Dos Santos; Tatiéle Nalin; Carolina Fischinger Moura de Souza; Eric W Triplett; Priscila Thiago Dobbler; Ida Vanessa Doederlein Schwartz; Luiz Fernando Wurdig Roesch
Journal:  PLoS One       Date:  2019-04-02       Impact factor: 3.240

4.  Very early-onset inflammatory bowel disease: Novel description in glycogen storage disease type Ia.

Authors:  William B Hannah; Ricardo C Ong; Margarita Nieto Moreno; Surekha Pendyal; Monica Abdelmalak; Judith Kelsen; Nancy M McGreal; Priya S Kishnani
Journal:  Mol Genet Metab Rep       Date:  2022-02-15

5.  Minimally invasive surgery for glycogen storage disease combined with inflammatory bowel disease: A case report.

Authors:  Jian Wan; Zi-Chao Zhang; Mu-Qing Yang; Xiao-Min Sun; Lu Yin; Chun-Qiu Chen
Journal:  World J Clin Cases       Date:  2021-06-16       Impact factor: 1.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.